Entera Bio Ltd.
ENTX · Biological Products, (No Diagnostic Substances) · 49.2M shares · +13%/yr ↑ dilution · EDGAR filings ↗
Reference price $1.30 · est. market cap ~$64M — last insider purchase, 2026-03-09 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D42Clinical/early-stage biotech — oral-peptide clinical micro-cap, funded.
Strengths
- Liquidity — current ratio 6.9 (66th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Going concernhowever, as a result of recurring losses, substantial doubt exists about the Company’s ability to continue as a going concern for a period of at least twelve months form the date of this Annual Report
- Chronic dilutionShare count +13%/yr over 3y (dilution, book value/share -23%)
- Net lossNet loss (net margin -27235.7%)
- Cash burnNegative free cash flow (-7.5M)
- Exec changeRecent 8-K item 5.02 8-K ↗
- Insider buyingInsider buying — 7 open-market buy(s) by 4 insider(s) (cluster of 4 insiders, ~$120,970, last 6mo) Form 4 ↗
- Revenue declineRevenue -76.8% YoY
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
0.0%
Operating margin
-27450.0%
Net margin
-27235.7%
Return on equity
-87.3%
Return on assets
-71.5%
Revenue growth (QoQ)
-76.8%
Current ratio
6.9×
Free cash flow
-$7M
Tangible book value
$13M
Cash & investments
$7M
Cash runway
4q
Stock comp / revenue
6547.6%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-07 | Galitzer Hillel | Grant | 73K | — |
| 2026-05-07 | Yaacov-Garbeli Dana | Grant | 58K | — |
| 2026-05-07 | Burshtein Gregory | Grant | 88K | — |
| 2026-03-09 | Germano Geno J | Buy | 20K | $1.30 |
| 2026-03-05 | Ellis Sean | Buy | 10K | $1.23 |
| 2026-02-12 | Rubin Steven D | Buy | 5.0K | $1.49 |
| 2026-02-10 | Taitel Haya | Buy | 7.5K | $1.48 |
| 2026-02-10 | Germano Geno J | Buy | 20K | $1.49 |
| 2026-02-09 | Rubin Steven D | Buy | 10K | $1.20 |
| 2026-02-09 | Ellis Sean | Buy | 18K | $1.24 |
| 2026-01-01 | OSTROV GERALD M | Grant | 29K | — |
| 2026-01-01 | Ellis Sean | Grant | 25K | — |
| 2026-01-01 | Malca Yonatan | Grant | 30K | — |
| 2026-01-01 | LIEBERMAN GERALD M | Grant | 38K | — |
| 2026-01-01 | Taitel Haya | Grant | 26K | — |
| 2025-12-29 | Toledano Miranda Jayne | Buy | 11K | $1.81 |
| 2025-07-16 | Toledano Miranda Jayne | Grant | 137K | — |
| 2025-07-16 | Toledano Miranda Jayne | Grant | 44K | — |
| 2025-07-16 | Burshtein Gregory | Grant | 26K | — |
| 2025-07-16 | Yaacov-Garbeli Dana | Grant | 26K | — |
| 2025-04-28 | Galitzer Hillel | Grant | 26K | — |
| 2025-04-01 | LIEBERMAN GERALD M | Option exercise | 24K | $1.00 |
| 2025-01-15 | Taitel Haya | Grant | 6.9K | — |
| 2025-01-15 | OSTROV GERALD M | Grant | 8.0K | — |
| 2025-01-15 | Malca Yonatan | Grant | 8.2K | — |
| 2025-01-15 | LIEBERMAN GERALD M | Grant | 11K | — |
| 2025-01-15 | Ellis Sean | Grant | 7.1K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05965167 ↗ | Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo Hypoparathyroidism, Osteoporosis | PHASE1 | Completed | 2026-02-08 |
| NCT04003467 ↗ | A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass Osteoporosis | PHASE2 | Completed | 2021-04-27 |
| NCT03516773 ↗ | Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism Hypoparathyroidism | PHASE2 | Completed | 2018-12-05 |
| NCT02571140 ↗ | A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects Drug Safety and Bioavailability | PHASE1 | Completed | 2017-08-01 |
| NCT02152228 ↗ | A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism Hypoparathyroidism | PHASE2 | Completed | 2015-06-01 |
| NCT02202603 ↗ | A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects Drug Safety | PHASE1 | Completed | 2013-08-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Supply chain
Customers (1)
Suppliers (0)
Named in the 10-K; linked when we track them.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-05-08 | ResultsReg FDExhibits | filing ↗ |
| 2026-04-03 | Material agreement3.02Exhibits | filing ↗ |
| 2026-03-27 | ResultsReg FDExhibits | filing ↗ |
| 2026-03-04 | Reg FDExhibits | filing ↗ |
| 2026-02-09 | Exec/director changeReg FDExhibits | filing ↗ |
| 2026-02-04 | Material agreementExec/director changeReg FDExhibits | filing ↗ |
| 2025-11-14 | ResultsReg FDExhibits | filing ↗ |
| 2025-08-08 | ResultsReg FDExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-05-08 | 2026-05-08 | 0001178913-26-002455 ↗ |
| 10-Q | 2026-05-08 | 2026-03-31 | 0001178913-26-002458 ↗ |
| 8-K | 2026-04-03 | 2026-04-01 | 0001178913-26-002001 ↗ |
| 10-K | 2026-03-27 | 2025-12-31 | 0001178913-26-001797 ↗ |
| 8-K | 2026-03-27 | 2026-03-27 | 0001178913-26-001792 ↗ |
| 8-K | 2026-03-04 | 2026-03-04 | 0001178913-26-000714 ↗ |
| 8-K | 2026-02-09 | 2026-02-04 | 0001178913-26-000355 ↗ |
| 8-K | 2026-02-04 | 2026-01-29 | 0001178913-26-000300 ↗ |
| 8-K | 2025-11-14 | 2025-11-14 | 0001178913-25-003851 ↗ |
| 10-Q | 2025-11-14 | 2025-09-30 | 0001178913-25-003852 ↗ |
| 8-K | 2025-08-08 | 2025-08-08 | 0001178913-25-002701 ↗ |
| 10-Q | 2025-08-08 | 2025-06-30 | 0001178913-25-002702 ↗ |